Merck & Co in-licenses Chimerix antiviral; Fiocruz to make ARVs in Africa
USA-based Chimerix, a venture-funded biotech focused on developing novel oral antivirals, has announced a license agreement granting US drugs giant Merck & Co (NYSE: MRK) exclusive worldwide rights to CMX157, its second clinical-stage antiviral compound, currently being evaluated to treat HIV infection.
Under the terms of the accord, Merck gains exclusive worldwide rights and will be responsible for development and commercialization of CMX157. In return, Chimerix will receive $17.5 million upfront payment and will be eligible for up to $151 million in milestone payments, as well as royalties on future sales.
Similar to lead development candidate Chimerix’ CMX001, CMX157 uses Chimerix’ lipid-antiviral-conjugate technology with the aim of creating a well-tolerated and highly potent new chemical entity with broad-spectrum antiviral activity and reduced toxicities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze